Yangtze River Pharmaceutical Group led Binhui Biopharm's $47m series B-plus round while Sigfox has been snapped up by UnaBiz for under $30m after raising over $300m.

Funding

China-based oncolytic virus therapeutics developer Binhui Biopharm has raised approximately $47m in a series B-plus round led by pharmaceutical group Yangtze River, DealStreetAsia reported yesterday. The round included medical product distributor Jointown Pharmaceutical Group, DNV Capital, Ming Capital and Hubei Provincial High-Tech Industry Investment Group.

Intigriti, the Belgium-based operator of an online bug bounty platform, received €21.1m ($22.5m) in series B funding today from investors including energy utility EnBW’s corporate venturing unit, EnBW New Ventures. Venture capital firm Octopus…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn